The U.S. health regulator has withdrawn emergency-use authorization for AstraZeneca's COVID-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.
about the effectiveness of monoclonal antibodies such as Evusheld against newer variants.
The drugmaker plans to continue to share relevant data with the FDA and other health authorities regarding Evusheld and SARS-CoV-2 variants.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
FDA halts authorization of Evusheld, citing medication insufficient against viral COVID-19 variantsSeveral antibody therapies used against Covid-19 earlier in the pandemic are no longer available because the virus has evolved and they are no longer effective.
Leer más »
With rise of new coronavirus variants, FDA halts authorization of Evusheld | CNNThe US Food and Drug Administration on Thursday halted the emergency use authorization of Evusheld because it does not appear to protect against Covid-19 from viral variants currently circulating in the United States.
Leer más »
FDA panel endorses changing primary COVID vaccinesAn FDA expert panel on Thursday unanimously recommended that the U.S. overhaul its pandemic vaccine strategy and replace initial doses of original COVID shots with bivalent ones that target specific Omicron subvariants.
Leer más »